Sign up here to receive news about future trials and FSHD related information. We will not share your email adress with third parties.


FSHD Nordic is a private initiative to try raise awareness in the Nordic region and prepare the local FSHD community for future trials and accelerating getting therapeutics to the market once available.

Losmapimod Demonstrates Significant Slowing of FSHD

Durability of treatment response on reachable workspace was observed among those who continued losmapimod throughout the 96-week period and those who switched from placebo. New long-term findings from the phase 2b ReDUX4 trial (NCT04003974) showed that treatment with losmapimod (Fulcrum…